REM-话题@MedSci

#REM#

111篇内容 | 2809人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1752291, encodeId=2e991e52291a6, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=令人惊喜！Cell：阻断TREM2可增强肿瘤免疫疗法，小鼠模型肿瘤完全清除, objectType=article, longId=199451, objectId=a0b619945110, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0b619945110, replyNumber=0, likeNumber=82, createdTime=2021-05-23, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0b619945110, moduleTitle=令人惊喜！Cell：阻断TREM2可增强肿瘤免疫疗法，小鼠模型肿瘤完全清除, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0b619945110)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752294, encodeId=d9d41e52294f6, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=III期数据证明：IL-23单抗TREMFYA可连续5年，维持斑块状牛皮癣患者的皮肤清除率, objectType=article, longId=202204, objectId=7085202204a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7085202204a8, replyNumber=0, likeNumber=58, createdTime=2021-06-04, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7085202204a8, moduleTitle=III期数据证明：IL-23单抗TREMFYA可连续5年，维持斑块状牛皮癣患者的皮肤清除率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7085202204a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752289, encodeId=32991e5228909, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Neurology：REM睡眠行为障碍的危险因素, objectType=article, longId=199279, objectId=c1701992e9c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1701992e9c9, replyNumber=0, likeNumber=81, createdTime=2020-12-24, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1701992e9c9, moduleTitle=Neurology：REM睡眠行为障碍的危险因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1701992e9c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752288, encodeId=84c31e522884d, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=抗TNF-α单抗皮下制剂Remsima获批，治疗时间缩短至25分钟, objectType=article, longId=198566, objectId=a45b198566bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a45b198566bc, replyNumber=0, likeNumber=69, createdTime=2021-02-26, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a45b198566bc, moduleTitle=抗TNF-α单抗皮下制剂Remsima获批，治疗时间缩短至25分钟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a45b198566bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752284, encodeId=bb1c1e5228408, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=FDA批准治疗银屑病关节炎的**种白介素-23单抗TREMFYA（guselkumab）, objectType=article, longId=197593, objectId=979d19e59394, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=979d19e59394, replyNumber=0, likeNumber=88, createdTime=2020-09-23, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=979d19e59394, moduleTitle=FDA批准治疗银屑病关节炎的**种白介素-23单抗TREMFYA（guselkumab）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=979d19e59394)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752293, encodeId=29cd1e52293ac, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Acta Neuropathologica: 慢性创伤性脑病患者可能的REM睡眠行为障碍与病理学和接触运动年限的关系, objectType=article, longId=201144, objectId=4f29201144b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f29201144b2, replyNumber=0, likeNumber=53, createdTime=2021-04-06, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f29201144b2, moduleTitle=Acta Neuropathologica: 慢性创伤性脑病患者可能的REM睡眠行为障碍与病理学和接触运动年限的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f29201144b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752266, encodeId=95871e522664f, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=神速！Remdesivir治疗新型冠状病毒肺炎试验，1天就入组200例患者, objectType=article, longId=187407, objectId=18b818e40781, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18b818e40781, replyNumber=0, likeNumber=83, createdTime=2021-01-12, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18b818e40781, moduleTitle=神速！Remdesivir治疗新型冠状病毒肺炎试验，1天就入组200例患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18b818e40781)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752283, encodeId=8d0e1e52283ef, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=欧盟批准Gilead的remdesivir，治疗新冠病毒COVID-19感染, objectType=article, longId=197033, objectId=67e319e03325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67e319e03325, replyNumber=0, likeNumber=87, createdTime=2020-07-05, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67e319e03325, moduleTitle=欧盟批准Gilead的remdesivir，治疗新冠病毒COVID-19感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67e319e03325)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752275, encodeId=66ac1e522757d, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验, objectType=article, longId=191476, objectId=71041914e630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71041914e630, replyNumber=0, likeNumber=63, createdTime=2021-03-21, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71041914e630, moduleTitle=吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71041914e630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752281, encodeId=4a321e5228113, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=2020年EAN：AJOVY（fremanezumab）治疗难治性偏头痛安全有效, objectType=article, longId=194742, objectId=8ebd194e4268, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ebd194e4268, replyNumber=0, likeNumber=64, createdTime=2020-07-04, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ebd194e4268, moduleTitle=2020年EAN：AJOVY（fremanezumab）治疗难治性偏头痛安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ebd194e4268)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752285, encodeId=35db1e522854f, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Cell：髓系细胞免疫信号枢纽——TREM2, objectType=article, longId=198086, objectId=766f198086b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=766f198086b5, replyNumber=0, likeNumber=83, createdTime=2021-04-29, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=766f198086b5, moduleTitle=Cell：髓系细胞免疫信号枢纽——TREM2, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=766f198086b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752270, encodeId=52931e522706f, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=战疫中——单抗药和 Remdesivir 组合是救星吗？, objectType=article, longId=188491, objectId=478e18849102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=478e18849102, replyNumber=0, likeNumber=36, createdTime=2020-08-03, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=478e18849102, moduleTitle=战疫中——单抗药和 Remdesivir 组合是救星吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=478e18849102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752257, encodeId=980d1e5225727, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=durvalumab与tremelimumab的组合未能在NSCLC研究中击败化疗, objectType=article, longId=178104, objectId=13451e81046d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13451e81046d, replyNumber=0, likeNumber=63, createdTime=2019-08-30, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13451e81046d, moduleTitle=durvalumab与tremelimumab的组合未能在NSCLC研究中击败化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13451e81046d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752260, encodeId=abd71e5226055, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=NEJM：Apremilast治疗白塞病相关口腔溃疡, objectType=article, longId=183026, objectId=409018302667, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=409018302667, replyNumber=0, likeNumber=132, createdTime=2019-11-30, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=409018302667, moduleTitle=NEJM：Apremilast治疗白塞病相关口腔溃疡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=409018302667)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752277, encodeId=49f71e5227793, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=WHO意外泄漏临床试验显示，吉利德的remdesivir未能改善重症新冠COVID-19感染患者, objectType=article, longId=192964, objectId=bc3a1929646c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc3a1929646c, replyNumber=0, likeNumber=71, createdTime=2020-10-18, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc3a1929646c, moduleTitle=WHO意外泄漏临床试验显示，吉利德的remdesivir未能改善重症新冠COVID-19感染患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc3a1929646c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752271, encodeId=d1e81e52271c9, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=美国正式开启Remdesivir治疗COVID-19的临床试验，来看研究方案, objectType=article, longId=189017, objectId=d40918901ee3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d40918901ee3, replyNumber=0, likeNumber=50, createdTime=2020-05-03, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d40918901ee3, moduleTitle=美国正式开启Remdesivir治疗COVID-19的临床试验，来看研究方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d40918901ee3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752254, encodeId=ba181e52254e7, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效, objectType=article, longId=177388, objectId=8ab51e73889d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ab51e73889d, replyNumber=0, likeNumber=64, createdTime=2020-02-15, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ab51e73889d, moduleTitle=Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ab51e73889d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752264, encodeId=1d9d1e52264b9, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=美国“神药”Remdesivir轻松搞定新型冠状病毒肺炎，到底是什么来头？, objectType=article, longId=187126, objectId=880f18e126d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=880f18e126d2, replyNumber=0, likeNumber=78, createdTime=2020-12-23, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=880f18e126d2, moduleTitle=美国“神药”Remdesivir轻松搞定新型冠状病毒肺炎，到底是什么来头？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=880f18e126d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752280, encodeId=f8f01e52280c3, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=美国国立卫生研究院（NIH）：瑞德西韦（Remdesivir）对需吸氧的COVID-19患者最有益, objectType=article, longId=194727, objectId=5098194e27b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5098194e27b4, replyNumber=0, likeNumber=69, createdTime=2020-10-20, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5098194e27b4, moduleTitle=美国国立卫生研究院（NIH）：瑞德西韦（Remdesivir）对需吸氧的COVID-19患者最有益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5098194e27b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752265, encodeId=bf8f1e5226542, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=新冠肺炎药物Remdesivir（瑞德西韦）在2020年2月3日在中国开始临床试验，中日友好医院牵头, objectType=article, longId=187167, objectId=a46f18e167ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a46f18e167ba, replyNumber=0, likeNumber=61, createdTime=2020-05-28, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a46f18e167ba, moduleTitle=新冠肺炎药物Remdesivir（瑞德西韦）在2020年2月3日在中国开始临床试验，中日友好医院牵头, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a46f18e167ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

REM

2020-05-29

tongyongming (审核中...)

前往app查看评论内容

#REM#

令人惊喜！Cell：阻断TREM2可增强肿瘤免疫疗法，小鼠模型肿瘤完全清除

2021-05-23

tongyongming (审核中...)

前往app查看评论内容

#REM#

III期数据证明：IL-23单抗TREMFYA可连续5年，维持斑块状牛皮癣患者的皮肤清除率

2021-06-04

tongyongming (审核中...)

前往app查看评论内容

#REM#

Neurology：REM睡眠行为障碍的危险因素

2020-12-24

tongyongming (审核中...)

前往app查看评论内容

#REM#

抗TNF-α单抗皮下制剂Remsima获批，治疗时间缩短至25分钟

2021-02-26

tongyongming (审核中...)

前往app查看评论内容

#REM#

FDA批准治疗银屑病关节炎的**种白介素-23单抗TREMFYA（guselkumab）

2020-09-23

tongyongming (审核中...)

前往app查看评论内容

#REM#

Acta Neuropathologica: 慢性创伤性脑病患者可能的REM睡眠行为障碍与病理学和接触运动年限的关系

2021-04-06

tongyongming (审核中...)

前往app查看评论内容

#REM#

神速！Remdesivir治疗新型冠状病毒肺炎试验，1天就入组200例患者

2021-01-12

tongyongming (审核中...)

前往app查看评论内容

#REM#

欧盟批准Gilead的remdesivir，治疗新冠病毒COVID-19感染

2020-07-05

tongyongming (审核中...)

前往app查看评论内容

#REM#

吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验

2021-03-21

tongyongming (审核中...)

前往app查看评论内容

#REM#

2020年EAN：AJOVY（fremanezumab）治疗难治性偏头痛安全有效

2020-07-04

tongyongming (审核中...)

前往app查看评论内容

#REM#

Cell：髓系细胞免疫信号枢纽——TREM2

2021-04-29

tongyongming (审核中...)

前往app查看评论内容

#REM#

战疫中——单抗药和 Remdesivir 组合是救星吗？

2020-08-03

tongyongming (审核中...)

前往app查看评论内容

#REM#

durvalumab与tremelimumab的组合未能在NSCLC研究中击败化疗

2019-08-30

tongyongming (审核中...)

前往app查看评论内容

#REM#

NEJM：Apremilast治疗白塞病相关口腔溃疡

2019-11-30

tongyongming (审核中...)

前往app查看评论内容

#REM#

WHO意外泄漏临床试验显示，吉利德的remdesivir未能改善重症新冠COVID-19感染患者

2020-10-18

tongyongming (审核中...)

前往app查看评论内容

#REM#

美国正式开启Remdesivir治疗COVID-19的临床试验，来看研究方案

2020-05-03

tongyongming (审核中...)

前往app查看评论内容

#REM#

Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效

2020-02-15

tongyongming (审核中...)

前往app查看评论内容

#REM#

美国“神药”Remdesivir轻松搞定新型冠状病毒肺炎，到底是什么来头？

2020-12-23

tongyongming (审核中...)

前往app查看评论内容

#REM#

美国国立卫生研究院（NIH）：瑞德西韦（Remdesivir）对需吸氧的COVID-19患者最有益

2020-10-20

tongyongming (审核中...)

前往app查看评论内容

#REM#

新冠肺炎药物Remdesivir（瑞德西韦）在2020年2月3日在中国开始临床试验，中日友好医院牵头

2020-05-28

科室
- - 订阅+
  - 更多科室
工具
服务